Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):790-800. Abstract
Dance KV et al. Perceptions of clinical care and research among African-American patients with lymphoma. Leuk Lymphoma 2021;62(8):1860-8. Abstract
Fowler NH et al. Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39(15):1609-18. Abstract
Goldman A et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol 2021;78(18):1800-13. Abstract
Goldman ML et al. Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer 2021;127(18):3390-402. Abstract
Hutchings M et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. J Clin Oncol 2021;39(18):1959-70. Abstract
Kalakonda N et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7(7):e511-22. Abstract
Kumar A et al. Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma. J Clin Oncol 2021;39(20):2257-65. Abstract
Kuruvilla J et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22(4):512-24. Abstract
Matasar MJ et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(5):678-89. Abstract
Payne JB et al. Supporting decision-making on fertility preservation among adolescent and young adult women with cancer. Oncology (Williston Park) 2020;34(11):494-9. Abstract
Salles G et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21(7):978-88. Abstract
Sehn LH et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-65. Abstract
Smith-Graziani D, Flowers CR. Understanding and addressing disparities in patients with hematologic malignancies: Approaches for clinicians. Am Soc Clin Oncol Educ Book 2021;41:1-7. Abstract
Steiner RE et al. Pacific: A phase II study of brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin and prednisone for patients with untreated primary mediastinal large b-cell lymphoma. ASH 2021;Abstract 1408.
Straus DJ et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021;8(6):e410-21. Abstract
Westin JR et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol 2021;96(10):1295-1312. Abstract
Zhang S et al. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun 2021;12(1):2877. Abstract